Boylan JF - Search Results

1

High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097.

He W, Luistro L, Carvajal D, Smith M, Nevins T, Yin X, Cai J, Higgins B, Kolinsky K, Rizzo C, Packman K, Heimbrook D, Boylan JF. He W, et al. Among authors: boylan jf. Mol Oncol. 2011 Jun;5(3):292-301. doi: 10.1016/j.molonc.2011.01.001. Epub 2011 Jan 21. Mol Oncol. 2011. PMID: 21315665 Free PMC article.

2

Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.

Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D, Roberts J, Cai J, Berkofsky-Fessler W, Hilton H, Linn M, Flohr A, Jakob-Røtne R, Jacobsen H, Glenn K, Heimbrook D, Boylan JF. Luistro L, et al. Among authors: boylan jf. Cancer Res. 2009 Oct 1;69(19):7672-80. doi: 10.1158/0008-5472.CAN-09-1843. Epub 2009 Sep 22. Cancer Res. 2009. PMID: 19773430 Free PMC article.

3

Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation.

Wang H, Daouti S, Li WH, Wen Y, Rizzo C, Higgins B, Packman K, Rosen N, Boylan JF, Heimbrook D, Niu H. Wang H, et al. Among authors: boylan jf. Cancer Res. 2011 Aug 15;71(16):5535-45. doi: 10.1158/0008-5472.CAN-10-4351. Epub 2011 Jun 24. Cancer Res. 2011. PMID: 21705440

4

Discovery of siRNA lipid nanoparticles to transfect suspension leukemia cells and provide in vivo delivery capability.

He W, Bennett MJ, Luistro L, Carvajal D, Nevins T, Smith M, Tyagi G, Cai J, Wei X, Lin TA, Heimbrook DC, Packman K, Boylan JF. He W, et al. Among authors: boylan jf. Mol Ther. 2014 Feb;22(2):359-370. doi: 10.1038/mt.2013.210. Epub 2013 Sep 3. Mol Ther. 2014. PMID: 24002693 Free PMC article.

5

BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.

Chen B, Tardell C, Higgins B, Packman K, Boylan JF, Niu H. Chen B, et al. Among authors: boylan jf. PLoS One. 2012;7(8):e42598. doi: 10.1371/journal.pone.0042598. Epub 2012 Aug 3. PLoS One. 2012. PMID: 22880048 Free PMC article.

6

Identification of novel, potent and selective inhibitors of Polo-like kinase 1.

Chen S, Bartkovitz D, Cai J, Chen Y, Chen Z, Chu XJ, Le K, Le NT, Luk KC, Mischke S, Naderi-Oboodi G, Boylan JF, Nevins T, Qing W, Chen Y, Wovkulich PM. Chen S, et al. Among authors: boylan jf. Bioorg Med Chem Lett. 2012 Jan 15;22(2):1247-50. doi: 10.1016/j.bmcl.2011.11.052. Epub 2011 Dec 1. Bioorg Med Chem Lett. 2012. PMID: 22172702

7

Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors.

Dantas-Barbosa C, Bergthold G, Daudigeos-Dubus E, Blockus H, Boylan JF, Ferreira C, Puget S, Abely M, Vassal G, Grill J, Geoerger B. Dantas-Barbosa C, et al. Among authors: boylan jf. Anticancer Drugs. 2015 Mar;26(3):272-83. doi: 10.1097/CAD.0000000000000190. Anticancer Drugs. 2015. PMID: 25486598

8

Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.

Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ. Tolcher AW, et al. Among authors: boylan jf. J Clin Oncol. 2012 Jul 1;30(19):2348-53. doi: 10.1200/JCO.2011.36.8282. Epub 2012 Apr 23. J Clin Oncol. 2012. PMID: 22529266 Free PMC article. Clinical Trial.

9

The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma.

Huynh C, Poliseno L, Segura MF, Medicherla R, Haimovic A, Menendez S, Shang S, Pavlick A, Shao Y, Darvishian F, Boylan JF, Osman I, Hernando E. Huynh C, et al. Among authors: boylan jf. PLoS One. 2011;6(9):e25264. doi: 10.1371/journal.pone.0025264. Epub 2011 Sep 29. PLoS One. 2011. PMID: 21980408 Free PMC article.

10

Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G₁-S Checkpoint.

Zhu D, Xu S, Deyanat-Yazdi G, Peng SX, Barnes LA, Narla RK, Tran T, Mikolon D, Ning Y, Shi T, Jiang N, Raymon HK, Riggs JR, Boylan JF. Zhu D, et al. Among authors: boylan jf. Mol Cancer Ther. 2018 Aug;17(8):1727-1738. doi: 10.1158/1535-7163.MCT-17-1084. Epub 2018 Jun 4. Mol Cancer Ther. 2018. PMID: 29866747

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

69 results

Search Page

Filters